The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistantStaphylococcus aureus: vancomycin and linezolid

Should the Currently Recommended Twice-Daily Dosing Still be Considered the Most Appropriate Regimen for Treating MRSA Ventilator-Associated Pneumonia with Vancomycin?

(2009) Federico Pea et al.   CLINICAL PHARMACOKINETICS

Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pneumonia Caused by Methicillin‐ResistantStaphylococcus aureus

(2008) Ethan Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

Skin and Soft‐Tissue Infections Caused by Community‐Acquired Methicillin‐ResistantStaphylococcus aureus

(2008) Martin E. Stryjewski et al.   CLINICAL INFECTIOUS DISEASES

United States resistance surveillance results for linezolid (LEADER Program for 2007)

(2008) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections

(2008) J. Majcher-Peszynska et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Prevention and Treatment of Seasonal Influenza

(2008) W. Paul Glezen   NEW ENGLAND JOURNAL OF MEDICINE